Actemra (tocilizumab) Product Information (PI) - Roche Australia
Actemra (tocilizumab) Product Information (PI) - Roche Australia
Actemra (tocilizumab) Product Information (PI) - Roche Australia
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
A statistically significant superior treatment effect was seen in favour of ACTEMRA<br />
over adalimumab in control of disease activity from baseline to week 24 for the primary<br />
endpoint of change in DAS28 and for all secondary endpoints (Table 4).<br />
Table 4 Efficacy Results for Study WA19924<br />
ADA + Placebo<br />
(IV)<br />
n = 162<br />
ACT + Placebo<br />
(SC)<br />
n = 163<br />
Primary Endpoint - Mean Change from baseline at Week 24<br />
DAS28 (adjusted mean) -1.8 -3.3<br />
p-value (a)<br />
Difference in adjusted mean (95% CI) -1.5 (-1.8, -1.1)